$$
k _ { 1 } \cup \cup E 2 9
$$

# 1.0 Submitted By:

Annette Hellie   
Senior Staff Regulatory Affairs Beckman Coulter, Inc.   
250 S. Kraemer Boulevard   
M/S E1.SE.01   
Brea, California 92821   
Telephone: (714) 961-4517   
Email: athellie@beckman.com

# 2.0 Date Submitted:

July 2, 2014

# 3.0 Device Name(s):

3.1 Proprietary Names UniCel DxC SYNCHRON Systems Hemoglobin A1c3 (HbA1c3) Reagent

3.2 Classification Name Glycosylated hemoglobin assay 21 CFR $\ S$ 864.7470 [LCP]

# 4.0 Predicate Device:

<table><tr><td rowspan=1 colspan=1>Candidate(s)</td><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>Manufacturer</td><td rowspan=1 colspan=1>DocketNumber</td></tr><tr><td rowspan=1 colspan=1>UniCel DxCSYNCHRON SystemsHemoglobin A1c(HbA1c3) Reagent</td><td rowspan=1 colspan=1>UniCel DxCSYNCHRON SystemsHemoglobin A1c-(HbA1c-) Reagent</td><td rowspan=1 colspan=1>BeckmanCoulter, Inc.</td><td rowspan=1 colspan=1>K121492</td></tr></table>

# 5.0 Description:

The UniCel DxC SYNCHRON Systems Hemoglobin A1c3 (HbA1c3) Reagent is intended for the quantitative determination of hemoglobin A1c concentration in human whole blood. The UniCel DxC Systems utilize two unique cartridges, Hb3 and A1c3, to determine hemoglobin A1c concentration as a ratio of total hemoglobin.

Hb3 reagent is used to measure total hemoglobin concentration by a colorimetric method. The system automatically proportions the appropriate sample and reagent volumes into the cuvette. The ratio used is one part sample to 8.6 parts reagent. The system monitors the change in absorbance at 410 nanometers. This change in absorbance is directly proportional to the concentration of total hemoglobin in the sample and is used by the system to calculate and express total hemoglobin concentration.

A1c3 reagent is used to measure the hemoglobin A1c concentration by a turbidimetric immunoinhibition method. In the reaction, hemoglobin A1c antibodies combine with hemoglobin A1c from the sample to form soluble antigen-antibody complexes. Polyhaptens from the reagent then bind with the excess antibodies and the resulting agglutinated complex is measured turbidimetrically. The system automatically proportions the appropriate sample and reagent volumes into the cuvette. The ratio used is one part sample to 28 parts reagent. The system monitors the change in absorbance at 340 nanometers. This change in absorbance is inversely proportional to the concentration of hemoglobin A1c in the sample and is used by the systems to calculate and express hemoglobin A1c concentration as a ratio of total hemoglobin.

# 6.0 Intended Use:

The UniCel DxC Synchron Systems Hemoglobin A1c3 (HbA1c3) Reagent, when used in conjunction with UniCel DxC 600/800 SYNCHRON Systems, UniCel DxC SYNCHRON Systems HbA1c3 Calibrators and HbDIL reagent, is intended for the quantitative determination of hemoglobin A1c concentration in human whole blood.

The A1c3 and Hb3 values generated as part of the HbA1c3 assay are intended for use in the calculation of the A1c3/Hb3 ratio and must not be used individually.

Measurement of hemoglobin A1c measures long-term glycemic control in patients with diabetes mellitus.

# 7.0 Comparison to Predicate(s):

The following table shows similarities and differences between the predicate identified in Section 4.0 of this summary.

# Similarities to the Predicate

<table><tr><td rowspan="3">DxC HbA1c3 Reagent levels/formulation</td><td>Intended Use</td><td>Predicate: "The Hemogiobin A1c- reagent, when used in conjunction with UniCel DxC 600/800 SYNCHRON Systems, UniCel DxC SYNCHRON Systems HbA1c- Calibrators and SYNCHRON and AU Systems Hemolyzing Reagent, is intended for the quantitative determination of hemoglobin A1c concentration in human whole</td></tr><tr><td>Same:</td><td>blood." "The UniCel DxC Synchron Systems Hemoglobin A1c3 (HbA1c) Reagent,when used in conjunction with UniCel DxC 600/800 SYNCHRON Systems, UniCel DxC SYNCHRON Systems HbA1c3 Calibrators and HbDIL reagent, is intended for the quantitative determination of hemoglobin A1c concentration in human whole blood." Note: Hemolyzing Reagent (offline sample preparation) = HbDIL (online</td></tr><tr><td>Reagent formulations Calibrator</td><td>sample preparation) same formulation Same</td></tr><tr><td colspan="1" rowspan="1">Calibratortraceability</td><td colspan="1" rowspan="1">IFCC HbA1c reference method</td></tr><tr><td colspan="1" rowspan="1">AcceptableAnticoagulants</td><td colspan="1" rowspan="1">EDTA &amp; heparin whole blood.K2-EDTAK3-EDTALithium HeparinSodium Heparin</td></tr><tr><td colspan="1" rowspan="1">SpecimenSbility</td><td colspan="1" rowspan="1">Whole blood samples stable for 8 hours at 15° to 25°C7 days at 2 - 8°C3 months at -15° to -20°18 months at -70°C (literature reference)</td></tr><tr><td colspan="1" rowspan="1">Analytical Range</td><td colspan="1" rowspan="1">Hb- 6.0 - 24 g/dLA1c- 0.30 - Cal 5 g/dL%HbA1c 4.0 - 17% 9 (NGSP)</td></tr><tr><td colspan="1" rowspan="1">Technology</td><td colspan="1" rowspan="1">Colorimetric</td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">Turbidimetric immunoinhibition</td></tr></table>

Differences From The Predicate   

<table><tr><td>DxC HbA1c3 Reagent</td><td>Sample preparation</td><td>New device employs on-line sample dilution utilizing same formulation of hemolyzing reagent.</td></tr><tr><td></td><td>Reagent volumes/tests per kit Hemoglobin Reagent (103 mL)</td><td>HbA1c3 Two A1c3 Cartridges (125 tests/cartridge) Antibody Reagent (50 mL) Polyhapten Reagent (12.7 mL) Two Hb3 Cartridge (125 tests/cartridge) Hemoglobin Reagent (42 mL) HbA1c- Two A1c- Cartridges (200 tests/cartridge) Antibody Reagent (64 mL) Polyhapten Reagent (16.9 mL) One Hb- Cartridge (400 tests/cartridge)</td></tr></table>

# 8.0 Summary of Performance Data:

The data in the Premarket Notification on safety and effectiveness supports a finding of substantial equivalence to chemistry test systems already in commercial distribution. Equivalence is demonstrated through method comparison, linearity, and imprecision, and sensitivity experiments.

DxC Method Comparison Summary   

<table><tr><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>Units</td><td rowspan=1 colspan=1>SampleRange</td><td rowspan=1 colspan=1>AcceptanceCriteria</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>DxC 600</td><td rowspan=1 colspan=1>% HbA1c(NGSP)</td><td rowspan=1 colspan=1>4.4 to16.6%bA1c(NGSP)</td><td rowspan=1 colspan=1>Slope 1.0 ± 0.05Intercept≤ ± 0.50R ≥ 0.97</td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>0.998</td><td rowspan=1 colspan=1>1.031</td><td rowspan=1 colspan=1>-0.267</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1>DxC 800</td><td rowspan=1 colspan=1>% HbA1c(NGSP)</td><td rowspan=1 colspan=1>4.3 to15.9%bBA1c(NGSP)</td><td rowspan=1 colspan=1>Slope 1.0 ± 0.05Intercept≤ ± 0.50R ≥ 0.97</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>0.999</td><td rowspan=1 colspan=1>1.031</td><td rowspan=1 colspan=1>-0.294</td><td rowspan=1 colspan=1>Pass</td></tr></table>

Anticoagulant Study Summary   

<table><tr><td rowspan=1 colspan=1>Anticoagulant</td><td rowspan=1 colspan=1>Level of AnticoagulantTested</td><td rowspan=1 colspan=1>Test Criteria</td><td rowspan=1 colspan=1>Deming Regression Analysis</td></tr><tr><td rowspan=1 colspan=1>K3-EDTA</td><td rowspan=1 colspan=1>1.74 mg/mL</td><td rowspan=1 colspan=1>Slope 1.0 ± 0.05Intercept &lt;± 0.75</td><td rowspan=1 colspan=1>Y = 1.012X - 0.043;R = 0.999</td></tr><tr><td rowspan=1 colspan=1>Lithium Heparin</td><td rowspan=1 colspan=1>15.8 USP units/mL</td><td rowspan=2 colspan=1>R &gt; 0.97</td><td rowspan=1 colspan=1>Y =1.007X-0.034;R = 0.999</td></tr><tr><td rowspan=1 colspan=1>Sodium Heparin</td><td rowspan=1 colspan=1>15.8 USP units/mL</td><td rowspan=1 colspan=1>Y=1.007X-0.034;R= 0.999</td></tr></table>

CLSI EP5-A2 Precision Estimate Method Summary   

<table><tr><td colspan="1" rowspan="2">Type ofImprecision</td><td colspan="1" rowspan="2">Sample Type</td><td colspan="1" rowspan="2">No. DataPoints</td><td colspan="1" rowspan="2">Mean Value(%HbA1c)</td><td colspan="2" rowspan="1">EP5-A2 Calculated PointEstimates</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">% CV</td></tr><tr><td colspan="1" rowspan="5">Within-run(DxC 600)</td><td colspan="1" rowspan="1">Whole Blood Control 1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">5.5</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">1.24</td></tr><tr><td colspan="1" rowspan="1">Whole Blood Control 2</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">1.13</td></tr><tr><td colspan="1" rowspan="1">Human Whole Blood Sample 1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">8.9</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">0.96</td></tr><tr><td colspan="1" rowspan="1">Human Whole Blood Sample 2</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">6.3</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">1.30</td></tr><tr><td colspan="1" rowspan="1">Human Whole Blood Sample 3</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">4.8</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">1.52</td></tr><tr><td colspan="1" rowspan="5">Total(DxC 600)</td><td colspan="1" rowspan="1">Whole Blood Control 1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">5.5</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">1.56</td></tr><tr><td colspan="1" rowspan="1">Whole Blood Control 2</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">1.46</td></tr><tr><td colspan="1" rowspan="1">Human Whole Blood Sample 1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">8.9</td><td colspan="1" rowspan="1">0.14</td><td colspan="1" rowspan="1">1.56</td></tr><tr><td colspan="1" rowspan="1">Human Whole Blood Sample 2</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">6.3</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">1.62</td></tr><tr><td colspan="1" rowspan="1">Human Whole Blood Sample 3</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">4.8</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">1.93</td></tr><tr><td colspan="1" rowspan="5">Within-run(DxC 800)</td><td colspan="1" rowspan="1">Whole Blood Control 1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">5.4</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">1.13</td></tr><tr><td colspan="1" rowspan="1">Whole Blood Control 2</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">9.9</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">0.80</td></tr><tr><td colspan="1" rowspan="1">Human Whole Blood Sample 1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">8.9</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.81</td></tr><tr><td colspan="1" rowspan="1">Human Whole Blood Sample 2</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">6.3</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">1.16</td></tr><tr><td colspan="1" rowspan="1">Human Whole Blood Sample 3</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">4.6</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">1.34</td></tr><tr><td colspan="1" rowspan="5">Total(DxC 800)</td><td colspan="1" rowspan="1">Whole Blood Control 1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">5.4</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">1.61</td></tr><tr><td colspan="1" rowspan="1">Whole Blood Control 2</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">9.9</td><td colspan="1" rowspan="1">0.13</td><td colspan="1" rowspan="1">1.34</td></tr><tr><td colspan="1" rowspan="1">Human Whole Blood Sample 1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">8.9</td><td colspan="1" rowspan="1">0.13</td><td colspan="1" rowspan="1">1.47</td></tr><tr><td colspan="1" rowspan="1">Human Whole Blood Sample 2</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">6.3</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">1.72</td></tr><tr><td colspan="1" rowspan="1">Human Whole Blood Sample 3</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">4.6</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">1.89</td></tr></table>

Additional With-run Precision Study Summary   

<table><tr><td rowspan=2 colspan=1>Type ofImprecision</td><td rowspan=2 colspan=1>Sample Type</td><td rowspan=2 colspan=1>No. DataPoints</td><td rowspan=2 colspan=1>Mean Value(%HbA1c)</td><td rowspan=1 colspan=2>Calculated Point Estimates</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>% CV</td></tr><tr><td rowspan=1 colspan=1>Within-run(DxC 800)</td><td rowspan=1 colspan=1>Human Whole Blood Sample@14% HbA1c</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>14.6</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>1.03</td></tr><tr><td rowspan=1 colspan=1>Within-run(DxC 600)</td><td rowspan=1 colspan=1>Human Whole Blood Sample@14% HbA1c</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>14.6</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>1.10</td></tr></table>

$\mathsf { D } \mathbf { x } \mathsf { C }$ Interferences Summary   

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Interference Pool Details(5%, 7%, &amp; 10% HbA1c NGSP)</td><td rowspan=1 colspan=1>Highest LevelTested</td><td rowspan=1 colspan=1>ObservedEffect</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>Bitirubin(unconjugated)</td><td rowspan=1 colspan=1>Whole blood samples spiked withstock unconjugated bilirubin solution(Sigma)</td><td rowspan=1 colspan=1>30 mg/dL (0.3 g/L)</td><td rowspan=1 colspan=1>NSI*</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1>Lipemia</td><td rowspan=1 colspan=1>Whole blood samples spiked with afat emulsion(Intralipid)</td><td rowspan=1 colspan=1>1000 mg/dL (10g/L)</td><td rowspan=1 colspan=1>NSI</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1>RheumatoidFactor</td><td rowspan=1 colspan=1>Whole blood samples spiked withhigh RF positive material (Human)</td><td rowspan=1 colspan=1>2000 IU/mL(2 x 10 U/L)</td><td rowspan=1 colspan=1>NSI</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>Whole blood samples spiked withstock ascorbic acid solution (Sigma)</td><td rowspan=1 colspan=1>50 mg/dL (0.5 g/L)</td><td rowspan=1 colspan=1>NSI</td><td rowspan=1 colspan=1>Pass</td></tr></table>

$\bf { \dot { \delta } } \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \| \le \|$ Significant Interference (within $\overline { { \pm 6 \% } }$ mathematical)

# Specificity

The antibody used in this assay shows no cross-reactivity with HbA0, HbA1a, HbA1b, acetylated 1emoglobin, carbamylated hemoglobin, and glycated albumin.

No significant effect of HbS, HbD, HbE, HbC, and up to $10 \%$ HbF was observed with this assay. Glycated HbF is not detected by the A1c3 assay as it does not contain the glycated $\beta$ chain. However, HbF is measured in the Hb3 assay.

amples containing $> 1 0 \%$ HbF may result in lower than expected HbA1c3 results.

No significant efect of labile glycated hemoglobin (up to 2000 mg/dL, 5 hours at $+ 3 7 \%$ ) was observed with this assay.

Criteria: Recovery within $+ 1 - 7 \%$ of control sample for HbS, HbD, HbE and HbC. Recovery within $+ 1 - 1 0 \%$ of control sample for HbF and labile glycated hemoglobin.

# DxC Linearity Summary

<table><tr><td>Hb3 (6.0 - 24 g/dL)</td><td>A1c3 (0.30 - Cal 5* g/dL)</td><td>%HbA1c (NGSP) (4.0 - 17%)</td></tr><tr><td>Linear Regression Slope: 1.0 ± 0.1 Intercept: &lt; ± 1.0 (g/dL) R: &gt; 0.95</td><td>Linear Regression Slope: 1.0 ± 0.1 Intercept: &lt; ± 0.3 (g/dL) R: &gt; 0.95</td><td>Linear Regression Slope: 1.0 ± 0.1 Intercept: &lt;± 0.75 (%HbA1c NGSP) R: &gt; 0.95</td></tr><tr><td>DxC 600 Y = 0.992x - 0.1051; R = 0.9997</td><td>DxC 600 Y = 1.0007x - 0.0076; R = 0.9994</td><td>DxC 600 Y = 0.9905x + 0.0387; R = 0.994</td></tr><tr><td>DxC 800 Y = 0.998x - 0.1899; R = 0.9993</td><td>DxC 800 Y = 0.9907x + 0.0032; R = 0.9999</td><td>DxC 800 Y = 0.9839x + 0.0521; R = 0.9996</td></tr></table>

\*Cal 5 Value is printed on the HbA1c3 calibrator value assignment sheet included in the kit

# Reference Interval Summary

Each laboratory should establish its own reference intervals based upon its patient population. The reference intervals sted below were taken from literature and confirmed by internal esting.   

<table><tr><td rowspan=1 colspan=1>Interval</td><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Conventional Units</td></tr><tr><td rowspan=1 colspan=1>Literature</td><td rowspan=1 colspan=1>Whole Blood</td><td rowspan=1 colspan=1>NGSP 4.0 - 6.0%IFCC 20 - 42 mmol/mol</td></tr></table>

M Panteghin  al "mplementation f hemoglobin Ac results traceable to the FCC refence system: the way forward," Clinical Chemistry and Laboratory Medicine 45(8) (2007): 942-944.

# Conclusion:

As summarized, the HbA1c3 Reagent is substantially equivalent to the HbA1c- Reagent (K121492). Substantial equivalence has been demonstrated through performance to verify that the device functions as intended and that design specifications have been satisfied.

This 510(k) summary is being submited in accordance with the requirements of the Safe Medical Device Act of 1990 and the implementing regulation 21 CFR 807.92.

BECKMAN COULTER, INC. ANNETTE HELLIE 250 S. KRAEMER ST BREA CA 92821

Re: K140829 Trade/Device Name: UniCel DxC Synchron Systems Hemoglobin (HbA1c3) Reagent Regulation Number: 21 CFR 864.7470 Regulation Name: Glycosylated hemoglobin assay Regulatory Class: II Product Code: LCP Dated: May 29, 2014 Received: June 2, 2014

Dear Ms. Hellie:

We have reviewed your Section $\mathsf { s l } 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to iha  eeass  i il and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class lI (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809). please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://wwv.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also. please note the regulation entitled. "Misbranding by reference to premarkel notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803). please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers. International and Consuner Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResoureesforYou/Industry/default.htm.

Sincerely yours.

# Katherine Serrano -S

For : Courtncy H. Lias. Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

Indications for Use (Describe)

The UniCel DxC Synchron Systems Hemoglobin Alc3 (HbAlc3) Reagent, when used in conjunction with UniCel DxC 600/800 SYNCHRON Systems, UniCel DxC SYNCHRON Systems HbA1c3 Calibrators and HbDIL reagent, is intended for the quantitative determination of hemoglobin Alc concentration in human whole blood.

TheAlcn Hvu s parhe HAcyr hecu he/ ratio and must not be used individually.

Measmenteglobs eptes etho tesure-eucntol in atnts i mellitus.

# Stayce Beck -S

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.'

The burden time for this collection of infoation is estimated to average79 hours per response, including he time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the cllection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."